PapersFlow Research Brief
Systemic Sclerosis and Related Diseases
Research Guide
What is Systemic Sclerosis and Related Diseases?
Systemic sclerosis is a complex autoimmune disease characterized by fibrosis, autoantibodies, pulmonary involvement, vascular abnormalities including Raynaud's phenomenon and endothelial dysfunction, and dysregulated TGF-β signaling.
The field encompasses 90,317 papers on the pathogenesis, clinical manifestations, and treatment of systemic sclerosis. Research emphasizes fibrosis mechanisms, genetic markers, and immunosuppressive therapies. Key studies have established classification criteria and validated severity measures applicable to this condition.
Topic Hierarchy
Research Sub-Topics
TGF-β Signaling in Systemic Sclerosis Fibrosis
This sub-topic investigates TGF-β pathway activation, Smad signaling, and downstream fibrotic gene expression in SSc fibroblasts. Researchers target inhibitors and epigenetic modifiers for therapeutic intervention.
Autoantibodies in Systemic Sclerosis
Focuses on detection, specificity, and prognostic roles of anti-centromere, anti-topoisomerase I, and RNA polymerase III antibodies. Studies link autoantibodies to organ involvement and disease subsets.
Pulmonary Fibrosis in Systemic Sclerosis
Examines interstitial lung disease pathogenesis, high-resolution CT correlations, and biomarkers in SSc-associated pulmonary fibrosis. Research includes antifibrotic therapies and right heart strain.
Endothelial Dysfunction in Systemic Sclerosis
This sub-topic covers vascular injury mechanisms, Raynaud's phenomenon pathophysiology, and endothelial progenitor cell roles. Investigations include nitric oxide pathways and digital ulcers.
Immunosuppressive Therapy in Systemic SSc
Evaluates efficacy and safety of cyclophosphamide, mycophenolate mofetil, and biologics in SSc trials for skin, lung, and joint involvement. Includes combination regimens and long-term outcomes.
Why It Matters
Systemic sclerosis affects multiple organs, with pulmonary involvement and skin fibrosis driving morbidity, as shown in cross-sectional studies linking plasma Hsp90 levels to lung and skin disease progression (Štorkánová et al., 2021). Classification criteria from "Preliminary criteria for the classification of systemic sclerosis (scleroderma)" (Masi, 1980) enable early diagnosis in multicenter studies, distinguishing it from mimics like systemic lupus erythematosus. Fibrosis research, including "Cellular and molecular mechanisms of fibrosis" (Wynn, 2007), identifies TGF-β pathways targeted by therapies, while subsets defined in "Scleroderma (systemic sclerosis): classification, subsets and pathogenesis" (LeRoy et al., 2001) guide risk stratification for interstitial lung disease, impacting treatment in over 4,900 cited cases.
Reading Guide
Where to Start
"Preliminary criteria for the classification of systemic sclerosis (scleroderma)" (Masi, 1980) provides foundational diagnostic standards from multicenter comparisons, essential for understanding case identification before exploring pathogenesis.
Key Papers Explained
"Preliminary criteria for the classification of systemic sclerosis (scleroderma)" (Masi, 1980) establishes diagnostic benchmarks, which "Scleroderma (systemic sclerosis): classification, subsets and pathogenesis" (LeRoy et al., 2001) refines into limited and diffuse subsets with autoantibody links. "Cellular and molecular mechanisms of fibrosis" (Wynn, 2007) details TGF-β-driven processes underlying these subsets, extended by "Mechanisms of fibrosis: therapeutic translation for fibrotic disease" (Wynn and Ramalingam, 2012) to treatment strategies. "Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study" (Štorkánová et al., 2021) applies these to biomarkers for organ-specific progression.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent emphasis remains on fibrosis biomarkers like Hsp90 and TGF-β inhibition, with no new preprints in the last 6 months. Classification refinements continue from SLICC criteria influences (Petri et al., 2012), focusing on pulmonary fibrosis diagnostics (Raghu et al., 2018).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | APACHE II-A Severity of Disease Classification System | 1986 | Critical Care Medicine | 13.4K | ✕ |
| 2 | APACHE II: a severity of disease classification system. | 1985 | PubMed | 6.0K | ✕ |
| 3 | Evaluation of Diagnostic Criteria for Ankylosing Spondylitis | 1984 | Arthritis & Rheumatism | 5.6K | ✕ |
| 4 | Derivation and validation of the Systemic Lupus International ... | 2012 | Arthritis & Rheumatism | 5.1K | ✓ |
| 5 | Plasma Hsp90 levels in patients with systemic sclerosis and re... | 2021 | Scientific Reports | 5.0K | ✓ |
| 6 | Preliminary criteria for the classification of systemic sclero... | 1980 | Arthritis & Rheumatism | 4.9K | ✕ |
| 7 | Cellular and molecular mechanisms of fibrosis | 2007 | The Journal of Pathology | 4.3K | ✓ |
| 8 | Scleroderma (systemic sclerosis): classification, subsets and ... | 2001 | — | 4.0K | ✕ |
| 9 | Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ER... | 2018 | American Journal of Re... | 3.8K | ✕ |
| 10 | Mechanisms of fibrosis: therapeutic translation for fibrotic d... | 2012 | Nature Medicine | 3.3K | ✕ |
Frequently Asked Questions
What are the preliminary classification criteria for systemic sclerosis?
Preliminary criteria for systemic sclerosis were developed from multicenter studies comparing early-diagnosed cases with systemic lupus erythematosus, polymyositis/dermatomyositis, and Raynaud's phenomenon (Masi, 1980). These criteria focus on major and minor features like proximal diffuse scleroderma and sclerodactyly. They provide a basis for distinguishing systemic sclerosis from related conditions.
How do plasma Hsp90 levels relate to systemic sclerosis manifestations?
Plasma Hsp90 levels correlate with lung and skin involvement in systemic sclerosis patients, as demonstrated in a cross-sectional and longitudinal study (Štorkánová et al., 2021). Higher levels associate with disease severity. This biomarker offers insights into fibrotic progression.
What defines the cellular mechanisms of fibrosis in systemic sclerosis?
Fibrosis involves excess extracellular matrix deposition, including collagen, from chronic inflammation (Wynn, 2007). Persistent stimuli drive myofibroblast activation via TGF-β signaling. These processes underlie tissue hardening in systemic sclerosis.
What are the subsets of systemic sclerosis?
"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis" outlines limited and diffuse cutaneous subsets based on skin involvement extent (LeRoy et al., 2001). Subsets differ in autoantibody profiles and organ risks. This classification informs prognosis and management.
How is disease severity measured in systemic sclerosis patients?
APACHE II uses point scores from 12 physiologic measurements, age, and health status to quantify severity, applicable to systemic sclerosis complications (Knaus et al., 1985). It predicts outcomes in critical care. Validation confirms its utility across diseases.
What role does TGF-β signaling play in systemic sclerosis?
TGF-β signaling drives fibrosis central to systemic sclerosis pathogenesis. It promotes fibroblast activation and matrix production (Wynn, 2012). Therapeutic targeting of these mechanisms shows promise for fibrotic diseases.
Open Research Questions
- ? How can plasma Hsp90 levels be leveraged to predict longitudinal lung function decline in systemic sclerosis?
- ? What specific TGF-β pathway inhibitors most effectively halt fibrosis progression in systemic sclerosis models?
- ? Which genetic markers best differentiate systemic sclerosis subsets and predict pulmonary involvement?
- ? How do endothelial dysfunction and autoantibodies interact to initiate Raynaud's phenomenon in early systemic sclerosis?
- ? What immunosuppressive therapies optimize outcomes in diffuse cutaneous systemic sclerosis with interstitial lung disease?
Recent Trends
The field includes 90,317 works with established citation leaders like APACHE II (Knaus et al., 1985; 6050 citations) and fibrosis mechanisms (Wynn, 2007; 4342 citations), but growth rate data over 5 years is unavailable.
No preprints or news coverage emerged in the last 6-12 months, indicating steady maturation without recent surges.
Hsp90 biomarker studies (Štorkánová et al., 2021; 4991 citations) represent the most contemporary high-impact contribution on lung-skin correlations.
Research Systemic Sclerosis and Related Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Systemic Sclerosis and Related Diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers